阿根廷队列研究:垂直感染儿童HIV-1治疗前耐药与含蛋白酶抑制剂一线抗逆转录病毒治疗病毒学应答不良相关
阿根廷队列研究纳入39例垂直感染HIV-1儿童,开始以洛匹那韦/利托那韦为基础的一线抗逆转录病毒治疗,中位月龄5.0个月(IQR=3.0-9.0)。23%儿童存在治疗前耐药相关突变,其中6例为NNRTI相关耐药。治疗前耐药组及NNRTI耐药亚组病毒学抑制速度慢于无耐药组,CD4 T细胞组间相似。作者认为诊断时基线基因型检测对个体化治疗重要,治疗前耐药(尤其NNRTI耐药)病例需更密切监测一线方案。
要点
- 39例垂直感染HIV-1儿童中9例(23%)存在治疗前耐药相关突变,6例为NNRTI相关耐药。
- 治疗4-8周病毒载量下降≥1 log的比例:无耐药组87% vs 耐药组33% vs NNRTI耐药亚组16.7%。
- 病毒学抑制速度:无耐药组631天 vs 耐药组2134天(P=0.1249)、NNRTI耐药亚组2134天(P=0.0447),无耐药组约为后两组近四倍。
核心结论
- 垂直感染儿童诊断时HIV-1基线基因型检测对改善个体化治疗重要;治疗前耐药(尤其NNRTI耐药)病例需更密切监测一线抗逆转录病毒治疗方案,以避免早期病毒学失败和防止耐药进一步累积。
研究设计与样本
- 阿根廷队列研究,纵向评估39例垂直感染HIV-1儿童开始以洛匹那韦/利托那韦为基础的一线抗逆转录病毒治疗后的病毒学和免疫学参数,中位开始月龄5.0个月(IQR=3.0-9.0)。
- 按WHO突变列表定义治疗前耐药,比较有无基线治疗前耐药儿童病毒载量随时间的变化。
主要发现
- HIV-1 pol基因耐药相关突变在一线抗逆转录病毒治疗开始前存在于9例HIV-1感染儿童(23%)中(治疗前耐药组),其中6例携带NNRTI相关耐药突变(NNRTI耐药亚组)。
- 治疗开始后4-8周,病毒载量下降≥1 log的儿童比例:无耐药组87% vs 治疗前耐药组33% vs NNRTI耐药亚组16.7%。
- 随访期间,无耐药组儿童达到病毒学抑制的速度几乎为治疗前耐药组或NNRTI耐药亚组的四倍:无耐药组631天 vs 治疗前耐药组2134天(P=0.1249)、NNRTI耐药亚组2134天(P=0.0447)。
- CD4 T细胞在研究组间随时间保持相似。
临床怎么用
- 作者认为,垂直感染儿童诊断时HIV-1基线基因型检测对改善个体化治疗重要。
- 作者认为,治疗前耐药(尤其NNRTI耐药)病例需要更密切监测其一线抗逆转录病毒治疗方案,以避免早期病毒学失败和防止耐药进一步累积。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Increasing evidence from adult cohorts suggests an important role of HIV-1 pretreatment drug resistance (PDR) in ART failure, in spite of treatment being fully active according to baseline genotyping tests. Whether this is also true for children is unknown. METHODS: Virological and immunological parameters were longitudinally assessed in a group of 39 HIV-1 vertically infected children starting first-line lopinavir/ritonavir-based ART at a median of 5.0 months (IQR = 3.0-9.0). Evolution of viral load (VL) over time was compared between children with and without baseline PDR, as defined by the WHO mutation list. RESULTS: Resistance-associated mutations (RAMs) in the HIV-1 pol gene were present in nine HIV-1-infected children (23%) before initiation of first-line ART (PDR group). Of them, six carried RAMs associated with NNRTIs (NNRTI-PDR subgroup). At 4-8 weeks after ART initiation, the proportion of children achieving ≥1 log VL reduction was 87% for the no-PDR group versus 33% and 16.7% for the PDR group and the NNRTI-PDR subgroup, respectively. During follow-up, children with no PDR reached virological suppression almost four times faster than children with PDR or NNRTI-PDR [no-PDR = 631 days and PDR = 2134 days (P = 0.1249) and NNRTI-PDR = 2134 days (P = 0.0447)]. CD4 T cells remained similar between the study groups over time. CONCLUSIONS: HIV-1 baseline genotyping at diagnosis in vertically infected children is important for improved personalized medicine. While the mechanism is unclear, cases with PDR (particularly to NNRTIs) require closer monitoring of their first-line ART regimens in order to avoid early virological failures and prevent further accumulation of resistance.
引用
- Rozenszajn M, Arazi-Caillaud S, Taicz M, et al. HIV-1 pretreatment drug resistance in vertically infected children is associated with poor virological response to protease inhibitor (PI)-based first-line antiretroviral therapy (ART): results from a cohort study in Argentina. J Antimicrob Chemother. 2022. PMID: 35512329. doi:10.1093/jac/dkac138
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。